Bernard Moss

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3427212/publications.pdf

Version: 2024-02-01

546 papers	61,760 citations	466 130 h-index	1900 208 g-index
548 all docs	548 docs citations	548 times ranked	19212 citing authors

#	Article	IF	Citations
1	Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 8122-8126.	7.1	2,354
2	In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. Journal of Virology, 1988, 62, 139-147.	3.4	871
3	HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature, 1987, 328, 345-348.	27.8	844
4	General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. Journal of Virology, 1984, 49, 857-864.	3.4	743
5	Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature, 1986, 323, 725-728.	27.8	697
6	Methylated nucleotides block 5â€² terminus of HeLa cell messenger RNA. Cell, 1975, 4, 379-386.	28.9	653
7	Vaccinia virus: a selectable eukaryotic cloning and expression vector.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 7415-7419.	7.1	637
8	New mammalian expression vectors. Nature, 1990, 348, 91-92.	27.8	628
9	Nonreplicating vaccinia vector efficiently expresses recombinant genes.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10847-10851.	7.1	583
10	Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 1785-1789.	7.1	507
11	Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11341-11348.	7.1	495
12	The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.. Journal of Experimental Medicine, 1995, 181, 1047-1058.	8.5	479
13	Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature, 1985, 317, 813-815.	27.8	446
14	Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6126-6130.	7.1	446
15	Vaccinia virus: a tool for research and vaccine development. Science, 1991, 252, 1662-1667.	12.6	446
16	Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature, 1983, 302, 490-495.	27.8	445
17	gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of â€œSelfâ€•reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand. Journal of Experimental Medicine, 1998, 188, 277-286.	8.5	437
18	Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-inducedâ€‰apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1172-1176.	7.1	431

#	Article	IF	Citations
19	An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3105-3109.	7.1	428
20	A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science, 1990, 247, 454-456.	12.6	418
21	A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses. Journal of Biological Chemistry, 2003, 278, 51613-51621.	3.4	406
22	Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature, 2004, 428, 182-185.	27.8	405
23	Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 648-652.	7.1	401
24	Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6641-6646.	7.1	390
25	Structure of vaccinia virus late promoters. Journal of Molecular Biology, 1989, 210, 771-784.	4.2	374
26	Immunobiology and Pathogenesis of Hepatocellular Injury in Hepatitis B Virus Transgenic Mice. Science, 1990, 248, 361-364.	12.6	369
27	Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression. BioTechniques, 1997, 23, 1094-1097.	1.8	365
28	Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2982-2987.	7.1	359
29	Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. Journal of Virology, 1991, 65, 2047-2055.	3.4	350
30	Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity. EMBO Journal, 1997, 16, 4519-4530.	7.8	341
31	Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature, 1988, 335, 176-178.	27.8	339
32	Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. Journal of Virology, 1988, 62, 1849-1854.	3.4	339
33	Methylated nucleotides block 5'-terminus of vaccinia virus messenger RNA.. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72, 318-322.	7.1	336
34	Structure of vaccinia virus early promoters. Journal of Molecular Biology, 1989, 210, 749-769.	4.2	335
35	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell, 2013, 155, 531-539.	28.9	334
36	Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks.. Journal of Cell Biology, 1993, 121, 521-541.	5.2	332

#	Article	IF	Citations
37	Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 7462-7466.	7.1	325
38	Genome Sequence of a Human Tumorigenic Poxvirus: Prediction of Specific Host Response-Evasion Genes. Science, 1996, 273, 813-816.	12.6	322
39	Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. Journal of Virology, 1991, 65, 5910-5920.	3.4	322
40	Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science, 1990, 250, 827-830.	12.6	319
41	Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. Journal of Virology, 1986, 60, 436-449.	3.4	306
42	Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene, 1983, 25, 21-28.	2.2	302
43	Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7155-7159.	7.1	300
44	Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 6417-6421.	7.1	299
45	HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science, 1988, 240, 64-66.	12.6	297
46	Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science, 1987, 235, 1059-1062.	12.6	290
47	Vaccinia Virus Expression Vectors. Annual Review of Immunology, 1987, 5, 305-324.	21.8	289
48	Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature, 1984, 311, 67-69.	27.8	288
49	Transient dominant selection of recombinant vaccinia viruses. Journal of Virology, 1990, 64, 3108-3111.	3.4	285
50	Genome-wide analysis of vaccinia virus protein-protein interactions. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4879-4884.	7.1	282
51	Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell, 1982, 28, 315-324.	28.9	280
52	Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature, 1988, 335, 369-372.	27.8	266
53	Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. Journal of Virology, 1991, 65, 31-41.	3.4	264
54	Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9458-9463.	7.1	263

#	Article	IF	Citations
55	Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature, 1986, 320, 535-537.	27.8	260
56	Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1709-1714.	7.1	258
57	Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8964-8967.	7.1	255
58	Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9514-9518.	7.1	255
59	Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.. Journal of Experimental Medicine, 1987, 165, 408-416.	8.5	253
60	Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science, 1985, 227, 433-435.	12.6	251
61	Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature, 1984, 311, 578-579.	27.8	250
62	Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen. Journal of Immunology, 2000, 164, 4968-4978.	0.8	247
63	Poxvirus entry and membrane fusion. Virology, 2006, 344, 48-54.	2.4	238
64	Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. Journal of Virology, 1992, 66, 4170-4179.	3.4	237
65	Rifampicin : a Specific Inhibitor of Vaccinia Virus Assembly. Nature, 1969, 224, 1280-1284.	27.8	236
66	Poxvirus DNA Replication. Cold Spring Harbor Perspectives in Biology, 2013, 5, a010199-a010199.	5.5	235
67	Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Research, 1992, 20, 1293-1299.	14.5	233
68	Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. Journal of Virology, 1994, 68, 3015-3026.	3.4	232
69	Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science, 1985, 228, 737-740.	12.6	231
70	Human monkeypox and smallpox viruses: genomic comparison. FEBS Letters, 2001, 509, 66-70.	2.8	231
71	Deletion of the vaccinia virus growth factor gene reduces virus virulence. Journal of Virology, 1988, 62, 866-874.	3.4	229
72	Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression. Nature, 1987, 330, 259-262.	27.8	228

#	Article	IF	Citations
73	Colocalization of Transcription and Translation within Cytoplasmic Poxvirus Factories Coordinates Viral Expression and Subjugates Host Functions. Cell Host and Microbe, 2007, 2, 221-228.	11.0	226
74	Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 628-632.	7.1	225
75	Regulation of Vaccinia Virus Transcription. Annual Review of Biochemistry, 1990, 59, 661-688.	11.1	222
76	Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4590-4595.	7.1	214
77	Inhibition of HeLa Cell Protein Synthesis by the Vaccinia Virion. Journal of Virology, 1968, 2, 1028-1037.	3.4	214
78	Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. Journal of Virology, 1990, 64, 2149-2156.	3.4	212
79	Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. Journal of Virology, 1993, 67, 4732-4741.	3.4	211
80	Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations. Journal of Virology, 1983, 46, 530-537.	3.4	209
81	An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7472-7476.	7.1	208
82	A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science, 1989, 246, 118-121.	12.6	206
83	The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. Journal of Virology, 1992, 66, 1943-1950.	3.4	206
84	Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6743-6747.	7.1	204
85	Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature, 1988, 334, 258-260.	27.8	201
86	Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting. Journal of Virology, 2003, 77, 799-803.	3.4	197
87	Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11513-11518.	7.1	196
88	Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 3659-3663.	7.1	195
89	Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. Journal of Virology, 1990, 64, 4884-4892.	3.4	195
90	Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. Journal of Virology, 1992, 66, 7217-7224.	3.4	194

#	Article	IF	Citations
91	Interruption by Rifampin of an Early Stage in Vaccinia Virus Morphogenesis: Accumulation of Membranes Which Are Precursors of Virus Envelopes. Journal of Virology, 1970, 6, 519-533.	3.4	193
92	N6, O2â€²-dimethyladenosine a novel methylated ribonucleoside next to the 5â€² terminal of animal cell and virus mRNAs. Nature, 1975, 257, 251-253.	27.8	190
93	Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions. Journal of Virology, 2004, 78, 10230-10237.	3.4	189
94	Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. Journal of Virology, 1990, 64, 2448-2451.	3.4	187
95	Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination. Journal of Virology, 2001, 75, 5151-5158.	3.4	186
96	Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 1210-1214.	7.1	184
97	Homology between RNA polymerases of poxviruses, prokaryotes, and eukaryotes: nucleotide sequence and transcriptional analysis of vaccinia virus genes encoding 147-kDa and 22-kDa subunits.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 3141-3145.	7.1	184
98	Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene, 1995, 158, 157-162.	2.2	183
99	IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11537-11542.	7.1	183
100	Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell, 1981, 25, 805-813.	28.9	181
101	Poxvirus Cell Entry: How Many Proteins Does it Take?. Viruses, 2012, 4, 688-707.	3.3	179
102	Smallpox vaccines: targets of protective immunity. Immunological Reviews, 2011, 239, 8-26.	6.0	178
103	Role of DNA replication in vaccinia virus gene expression: A naked template is required for transcription of three late trans-activator genes. Cell, 1990, 61, 801-809.	28.9	172
104	Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. Journal of Virology, 1992, 66, 2934-2942.	3.4	171
105	Hemoglobin synthesis during amphibian metamorphosis. Journal of Molecular Biology, 1968, 32, 481-492.	4.2	168
106	Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus.. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72, 2525-2529.	7.1	168
107	Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 9273-9277.	7.1	166
108	Formation of a Vaccinia Virus Structural Polypeptide from a Higher Molecular Weight Precursor: Inhibition by Rifampicin. Proceedings of the National Academy of Sciences of the United States of America, 1970, 66, 677-684.	7.1	165

#	Article	IF	Citations
109	Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4512-4517.	7.1	165
110	Complete pathway for protein disulfide bond formation encoded by poxviruses. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6667-6672.	7.1	165
111	Vaccinia Virus Intracellular Movement Is Associated with Microtubules and Independent of Actin Tails. Journal of Virology, 2001, 75, 11651-11663.	3.4	163
112	Transcription of vaccinia virus early genes by enzymes isolated from vaccinia virions terminates downstream of a regulatory sequence. Cell, 1986, 46, 1029-1035.	28.9	162
113	T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science, 1986, 234, 728-731.	12.6	162
114	Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV. Journal of Virology, 2000, 74, 2740-2751.	3.4	162
115	Sequential Protein Synthesis Following Vaccinia Virus Infection. Journal of Virology, 1968, 2, 1016-1027.	3.4	162
116	Ultraviolet-Induced Cell Death Blocked by a Selenoprotein from a Human Dermatotropic Poxvirus. Science, 1998, 279, 102-105.	12.6	160
117	Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein. Journal of Infectious Diseases, 1992, 166, 1245-1250.	4.0	154
118	Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. Journal of Virology, 1993, 67, 3319-3325.	3.4	154
119	Protein composition of the vaccinia virus mature virion. Virology, 2007, 358, 233-247.	2.4	152
120	Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine. Journal of Virology, 2002, 76, 6138-6146.	3.4	151
121	Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. Journal of Infectious Diseases, 2011, 203, 610-619.	4.0	151
122	Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 11699-11703.	7.1	150
123	Complete Nucleotide Sequences of Two Adjacent Early Vaccinia Virus Genes Located Within the Inverted Terminal Repetition. Journal of Virology, 1982, 44, 637-646.	3.4	150
124	Identification of a vaccinia virus gene encoding a type I DNA topoisomerase.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 7478-7482.	7.1	148
125	The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.. Journal of Clinical Investigation, 1998, 102, 2072-2081.	8.2	148
126	Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 8638-8642.	7.1	146

#	Article	IF	Citations
127	Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3183-3188.	7.1	146
128	Visualization of Intracellular Movement of Vaccinia Virus Virions Containing a Green Fluorescent Protein-B5R Membrane Protein Chimera. Journal of Virology, 2001, 75, 4802-4813.	3.4	146
129	Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140. Journal of Virology, 2001, 75, 645-653.	3.4	145
130	Protein cleavage and poxvirus morphogenesis: Tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin. Journal of Molecular Biology, 1973, 81, 267-269.	4.2	144
131	Tandem repeats within the inverted terminal repetition of vaccinia virus DNA. Cell, 1980, 21, 277-284.	28.9	144
132	Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 5300-5304.	7.1	141
133	Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6773-6777.	7.1	141
134	Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge. Journal of Virology, 2000, 74, 2502-2509.	3.4	141
135	Vaccinia Virus Entry into Cells via a Low-pH-Dependent Endosomal Pathway. Journal of Virology, 2006, 80, 8899-8908.	3.4	141
136	Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines. Journal of Virology, 2002, 76, 7625-7631.	3.4	140
137	Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. Journal of Virology, 1996, 70, 3753-3762.	3.4	140
138	A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2357-2361.	7.1	138
139	The Envelope Protein Encoded by the A33R Gene Is Required for Formation of Actin-Containing Microvilli and Efficient Cell-to-Cell Spread of Vaccinia Virus. Journal of Virology, 1998, 72, 4192-4204.	3.4	138
140	Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes.. Journal of Experimental Medicine, 1986, 163, 1529-1538.	8.5	135
141	Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. Journal of Virology, 1988, 62, 1530-1534.	3.4	134
142	Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cells. Journal of Molecular Biology, 1989, 206, 333-348.	4.2	133
143	Poly(A) polymerase and a dissociable polyadenylation stimulatory factor encoded by vaccinia virus. Cell, 1991, 66, 1269-1278.	28.9	133
144	Calreticulin Interacts with Newly Synthesized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, Suggesting a Chaperone Function Similar to That of Calnexin. Journal of Biological Chemistry, 1996, 271, 97-103.	3.4	133

#	Article	IF	Citations
145	Poxvirus multiprotein entry-fusion complex. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18572-18577.	7.1	133
146	Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled. Journal of Virology, 1987, 61, 1098-1102.	3.4	133
147	Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. Journal of Virology, 1996, 70, 2797-2808.	3.4	132
148	Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65. Journal of Virology, 1994, 68, 1103-1114.	3.4	131
149	Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 1906-1910.	7.1	128
150	CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4818-4822.	7.1	128
151	Regulation of expression and nucleotide sequence of a late vaccinia virus gene. Journal of Virology, 1984, 51, 662-669.	3.4	128
152	An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself.. Journal of Experimental Medicine, 1990, 171, 571-576.	8.5	127
153	New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Research, 1990, 18, 4285-4285.	14.5	127
154	Immunity from Smallpox Vaccine Persists for Decades: A Longitudinal Study. American Journal of Medicine, 2008, 121, 1058-1064.	1.5	127
155	A viral member of the ERV1/ALR protein family participates in a cytoplasmic pathway of disulfide bond formation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12068-12073.	7.1	126
156	Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6403-6407.	7.1	124
157	Transcriptional and translational mapping and nucleotide sequence analysis of a vaccinia virus gene encoding the precursor of the major core polypeptide 4b. Journal of Virology, 1985, 56, 830-838.	3.4	124
158	Immunology 101 at poxvirus U: Immune evasion genes. Seminars in Immunology, 2001, 13, 59-66.	5.6	123
159	Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge. Journal of Virology, 2005, 79, 13454-13462.	3.4	123
160	Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily.. Journal of Virology, 1989, 63, 600-606.	3.4	123
161	Protein Kinase and Specific Phosphate Acceptor Proteins Associated with Vaccinia Virus Cores. Journal of Virology, 1972, 10, 417-424.	3.4	121
162	Extension of the transcriptional and translational map of the left end of the vaccinia virus genome to 21 kilobase pairs. Journal of Virology, 1981, 39, 733-745.	3.4	115

#	Article	IF	Citations
163	The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. Journal of Virology, 1997, 71, 3904-3915.	3.4	115
164	Cap-specific mRNA (nucleoside-O2'-)-methyltransferase and poly(A) polymerase stimulatory activities of vaccinia virus are mediated by a single protein.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2897-2901.	7.1	114
165	Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax. Journal of Virology, 2008, 82, 652-663.	3.4	114
166	Expression Profiling of the Intermediate and Late Stages of Poxvirus Replication. Journal of Virology, 2011, 85, 9899-9908.	3.4	114
167	Early transcription factor subunits are encoded by vaccinia virus late genes.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4401-4405.	7.1	111
168	The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Research, 2005, 65, 9991-9998.	0.9	111
169	Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2139-2144.	7.1	109
170	Methylation of Newly Synthesized Viral Messenger RNA by an Enzyme in Vaccinia Virus. Proceedings of the National Academy of Sciences of the United States of America, 1974, 71, 3014-3018.	7.1	108
171	Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein.. Journal of Experimental Medicine, 1989, 170, 2023-2035.	8.5	108
172	RNA polymerase-associated transcription specificity factor encoded by vaccinia virus.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3536-3540.	7.1	108
173	Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10112-10116.	7.1	108
174	Vaccinia virus thymidine kinase and neighboring genes: mRNAs and polypeptides of wild-type virus and putative nonsense mutants. Journal of Virology, 1983, 45, 62-72.	3.4	108
175	Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus. Journal of Virology, 1986, 60, 337-344.	3.4	108
176	Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 19-23.	7.1	107
177	Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10889-10894.	7.1	107
178	Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies. Journal of Virology, 2000, 74, 4236-4243.	3.4	106
179	Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes. Journal of Virology, 1993, 67, 3515-3527.	3.4	106
180	Expression of the vaccinia virus genome: Analysis and mapping of mRNAs encoded within the inverted terminal repetition. Cell, 1980, 21, 487-493.	28.9	105

#	Article	IF	Citations
181	Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. Science, 1984, 224, 397-399.	12.6	105
182	Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine. Journal of Infectious Diseases, 2011, 204, 164-173.	4.0	105
183	Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells. Journal of Virology, 1987, 61, 726-734.	3.4	105
184	Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. Journal of Virology, 1997, 71, 2674-2684.	3.4	105
185	Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein. Journal of Virology, 1998, 72, 8264-8272.	3.4	105
186	Sequence complexity and relative abundance of vaccinia virus mRNA's synthesized in vivo and in vitro. Journal of Virology, 1978, 26, 554-569.	3.4	104
187	Vaccinia Virus Structural Polypeptide Derived from a High-Molecular-Weight Precursor: Formation and Integration into Virus Particles. Journal of Virology, 1970, 6, 717-726.	3.4	102
188	Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization. Journal of Immunology, 2013, 190, 2720-2735.	0.8	99
189	An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. Journal of Virology, 1991, 65, 4051-4056.	3.4	99
190	Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 5908-5912.	7.1	98
191	Membrane fusion during poxvirus entry. Seminars in Cell and Developmental Biology, 2016, 60, 89-96.	5.0	97
192	Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol. Journal of Virology, 2004, 78, 3930-3940.	3.4	96
193	Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA. Journal of Virology, 1979, 30, 365-374.	3.4	96
194	Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate-class promoters. Journal of Virology, 1992, 66, 4710-4719.	3.4	96
195	Visualization of an inverted terminal repetition in vaccinia virus DNA.. Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 4863-4867.	7.1	95
196	Selective transcription of vaccinia virus genes in template dependent soluble extracts of infected cells. Cell, 1983, 35, 441-448.	28.9	95
197	Limited immunological recognition of critical malaria vaccine candidate antigens. Science, 1988, 242, 574-577.	12.6	95
198	Sequence of methylated nucleotides at the 5'-terminus of adenovirus-specific RNA. Journal of Virology, 1976, 17, 385-392.	3.4	95

#	Article	IF	Citations
199	Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12415-12420.	7.1	94
200	Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface. Journal of Virology, 2002, 76, 7863-7867.	3.4	94
201	Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1882-1887.	7.1	94
202	Characterization of a Second Vaccinia Virus mRNA-Decapping Enzyme Conserved in Poxviruses. Journal of Virology, 2007, 81, 12973-12978.	3.4	94
203	Degradation of Host MicroRNAs by Poxvirus Poly(A) Polymerase Reveals Terminal RNA Methylation as a Protective Antiviral Mechanism. Cell Host and Microbe, 2012, 12, 200-210.	11.0	94
204	Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein. Journal of Virology, 1991, 65, 4598-4608.	3.4	94
205	Perspective: Discovery of antivirals against smallpox. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11178-11192.	7.1	93
206	Inhibition of the Ubiquitin-Proteasome System Prevents Vaccinia Virus DNA Replication and Expression of Intermediate and Late Genes. Journal of Virology, 2009, 83, 2469-2479.	3.4	93
207	Bacterial-type DNA Holliday junction resolvases in eukaryotic viruses. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8926-8931.	7.1	92
208	Vaccinia Virus Entry into Cells Is Dependent on a Virion Surface Protein Encoded by the A28L Gene. Journal of Virology, 2004, 78, 2357-2366.	3.4	92
209	Mapping of the vaccinia virus DNA polymerase gene by marker rescue and cell-free translation of selected RNA. Journal of Virology, 1984, 49, 72-77.	3.4	92
210	Poxvirus Decapping Enzymes Enhance Virulence by Preventing the Accumulation of dsRNA and the Induction of Innate Antiviral Responses. Cell Host and Microbe, 2015, 17, 320-331.	11.0	90
211	Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. Journal of Virology, 1996, 70, 6418-6424.	3.4	90
212	Utilization of the guanylyltransferase and methyltransferases of vaccinia virus to modify and identify the 5â€²-terminals of heterologous RNA species. Biochemical and Biophysical Research Communications, 1977, 74, 374-383.	2.1	89
213	An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2344-2348.	7.1	88
214	Transcription of vaccinia virus early genes by a template-dependent soluble extract of purified virions. Journal of Virology, 1985, 56, 349-355.	3.4	88
215	Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2549-2553.	7.1	87
216	Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251. Journal of Virology, 2003, 77, 179-190.	3.4	87

#	Article	IF	Citations
217	Skin Mast Cells Protect Mice against Vaccinia Virus by Triggering Mast Cell Receptor S1PR2 and Releasing Antimicrobial Peptides. Journal of Immunology, 2012, 188, 345-357.	0.8	87
218	Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3519-3524.	7.1	87
219	Hybridization selection and cell-free translation of mRNA's encoded within the inverted terminal repetition of the vaccinia virus genome. Journal of Virology, 1981, 37, 284-294.	3.4	87
220	Polyadenylate Polymerase from Vaccinia Virions. Nature: New Biology, 1973, 245, 59-63.	4.5	86
221	Poxviruses as expression vectors. Current Opinion in Biotechnology, 1997, 8, 573-577.	6.6	85
222	Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys. Journal of Virology, 2001, 75, 2462-2467.	3.4	85
223	External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. Journal of Cell Biology, 2005, 170, 971-981.	5.2	85
224	Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8889-8893.	7.1	84
225	Mutational Analysis of the Assembly Domain of the HIV-1 Envelope Glycoprotein. AIDS Research and Human Retroviruses, 1993, 9, 589-594.	1.1	84
226	Vaccinia Virus A21 Virion Membrane Protein Is Required for Cell Entry and Fusion. Journal of Virology, 2005, 79, 9458-9469.	3.4	84
227	Resolution of vaccinia virus DNA concatemer junctions requires late-gene expression. Journal of Virology, 1989, 63, 1595-1603.	3.4	84
228	Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein. Journal of Virology, 2003, 77, 10684-10688.	3.4	82
229	Entry of Vaccinia Virus and Cell-Cell Fusion Require a Highly Conserved Cysteine-Rich Membrane Protein Encoded by the A16L Gene. Journal of Virology, 2006, 80, 51-61.	3.4	82
230	5'-Terminal and internal methylated nucleosides in herpes simplex virus type 1 mRNA. Journal of Virology, 1977, 23, 234-239.	3.4	82
231	Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. Journal of Virology, 1986, 57, 786-791.	3.4	82
232	Hemoglobin synthesis during amphibian metamorphosis. Journal of Molecular Biology, 1968, 32, 493-502.	4.2	81
233	A cellular factor is required for transcription of vaccinia viral intermediate-stage genes.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3794-3798.	7.1	81
234	Vaccinia Virus H2 Protein Is an Essential Component of a Complex Involved in Virus Entry and Cell-Cell Fusion. Journal of Virology, 2005, 79, 4744-4754.	3.4	80

#	Article	IF	Citations
235	Vaccinia Virus L1 Protein Is Required for Cell Entry and Membrane Fusion. Journal of Virology, 2008, 82, 8687-8694.	3.4	80
236	Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor. Journal of Virology, 1991, 65, 6101-6110.	3.4	80
237	Eukaryotic mRNA capping enzyme-guanylate covalent intermediate.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 340-344.	7.1	79
238	Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science, 1991, 252, 1310-1313.	12.6	79
239	The Product of the Vaccinia Virus L5R Gene Is a Fourth Membrane Protein Encoded by All Poxviruses That Is Required for Cell Entry and Cell-Cell Fusion. Journal of Virology, 2005, 79, 10988-10998.	3.4	79
240	The Membrane Fusion Step of Vaccinia Virus Entry Is Cooperatively Mediated by Multiple Viral Proteins and Host Cell Components. PLoS Pathogens, 2011, 7, e1002446.	4.7	79
241	The vaccinia virus H5R gene encodes late gene transcription factor 4: purification, cloning, and overexpression. Journal of Virology, 1996, 70, 6796-6802.	3.4	79
242	DNA Packaging Mutant: Repression of the Vaccinia Virus A32 Gene Results in Noninfectious, DNA-Deficient, Spherical, Enveloped Particles. Journal of Virology, 1998, 72, 5769-5780.	3.4	79
243	Resolution of linear minichromosomes with hairpin ends from circular plasmids containing vaccinia virus concatemer junctions. Cell, 1986, 45, 879-884.	28.9	78
244	Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R. Journal of Virology, 2005, 79, 6260-6271.	3.4	78
245	Identification of the vaccinia virus gene encoding an 18-kilodalton subunit of RNA polymerase and demonstration of a 5' poly(A) leader on its early transcript. Journal of Virology, 1990, 64, 3019-3024.	3.4	78
246	Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus. Journal of Virology, 1999, 73, 10199-10207.	3.4	78
247	Salmon Gill Poxvirus, the Deepest Representative of the Chordopoxvirinae. Journal of Virology, 2015, 89, 9348-9367.	3.4	77
248	Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. Journal of Virology, 1996, 70, 3407-3415.	3.4	77
249	CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9539-9543.	7.1	76
250	Glutaredoxin homolog encoded by vaccinia virus is a virion-associated enzyme with thioltransferase and dehydroascorbate reductase activities.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7060-7064.	7.1	76
251	Characterization of the Vaccinia Virus H3L Envelope Protein: Topology and Posttranslational Membrane Insertion via the C-Terminal Hydrophobic Tail. Journal of Virology, 2000, 74, 7508-7517.	3.4	76
252	Inducer-dependent conditional-lethal mutant animal viruses.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1511-1515.	7.1	75

#	Article	IF	Citations
253	Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine, 1999, 18, 392-397.	3.8	75
254	Vaccinia Virus Uracil DNA Glycosylase Has an Essential Role in DNA Synthesis That Is Independent of Its Glycosylase Activity: Catalytic Site Mutations Reduce Virulence but Not Virus Replication in Cultured Cells. Journal of Virology, 2003, 77, 159-166.	3.4	75
255	Identification of Wild-Derived Inbred Mouse Strains Highly Susceptible to Monkeypox Virus Infection for Use as Small Animal Models. Journal of Virology, 2010, 84, 8172-8180.	3.4	75
256	Deletion of a 9,000-base-pair segment of the vaccinia virus genome that encodes nonessential polypeptides. Journal of Virology, 1981, 40, 387-395.	3.4	75
257	Vaccinia Virus A36R Membrane Protein Provides a Direct Link between Intracellular Enveloped Virions and the Microtubule Motor Kinesin. Journal of Virology, 2004, 78, 2486-2493.	3.4	74
258	Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. Journal of Experimental Medicine, 2007, 204, 2733-2746.	8.5	74
259	Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes. MBio, 2021, 12, e0149521.	4.1	74
260	Multiple Roles for ATP in the Synthesis and Processing of mRNA by Vaccinia Virus: Specific Inhibitory Effects of Adenosine (Î²,Î³-Imido) Triphosphate. Journal of Virology, 1978, 27, 399-408.	3.4	74
261	DNA-dependent RNA polymerase subunits encoded within the vaccinia virus genome. Journal of Virology, 1987, 61, 1765-1771.	3.4	74
262	Multiple 3' ends of mRNA encoding vaccinia virus growth factor occur within a series of repeated sequences downstream of T clusters. Journal of Virology, 1986, 60, 320-323.	3.4	73
263	Regulation of Vaccinia Virus Morphogenesis: Phosphorylation of the A14L and A17L Membrane Proteins and C-Terminal Truncation of the A17L Protein Are Dependent on the F10L Kinase. Journal of Virology, 1999, 73, 3534-3543.	3.4	73
264	Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate. PLoS ONE, 2010, 5, e13983.	2.5	72
265	Poxvirus DNA primase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18724-18729.	7.1	71
266	Functional and structural interactions between measles virus hemagglutinin and CD46. Journal of Virology, 1995, 69, 3341-3349.	3.4	71
267	Role of the I7 Protein in Proteolytic Processing of Vaccinia Virus Membrane and Core Components. Journal of Virology, 2004, 78, 6335-6343.	3.4	70
268	Characterization of a Vaccinia Virus Mutant with a Deletion of the D10R Gene Encoding a Putative Negative Regulator of Gene Expression. Journal of Virology, 2006, 80, 553-561.	3.4	70
269	Targeting of a multicomponent transcription apparatus into assembling vaccinia virus particles requires RAP94, an RNA polymerase-associated protein. Journal of Virology, 1994, 68, 1360-1370.	3.4	70
270	5'-Terminal capping of RNA by guanylyltransferase from HeLa cell nuclei.. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 3758-3761.	7.1	68

#	Article	IF	Citations
271	Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp160 and Analysis of Its Immunogenicity. AIDS Research and Human Retroviruses, 1989, 5, 159-171.	1.1	68
272	Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein (p137) Individually or as a Heterodimer. Journal of Biological Chemistry, 2004, 279, 52210-52217.	3.4	68
273	Genome-Wide Analysis of the 5â€² and 3â€² Ends of Vaccinia Virus Early mRNAs Delineates Regulatory Sequences of Annotated and Anomalous Transcripts. Journal of Virology, 2011, 85, 5897-5909.	3.4	68
274	The repression and induction by thyroxin of hemoglobin synthesis during amphibian metamorphosis.. Proceedings of the National Academy of Sciences of the United States of America, 1965, 54, 967-974.	7.1	67
275	Vaccinia Virus F9 Virion Membrane Protein Is Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein. Journal of Virology, 2006, 80, 9455-9464.	3.4	67
276	Vaccinia virus directed RNA and protein synthesis in the presence of rifampicin. Biochemical and Biophysical Research Communications, 1969, 36, 858-865.	2.1	66
277	Preclinical Studies of Human Immunodeficiency Virus/AIDS Vaccines: Inverse Correlation between Avidity of Anti-Env Antibodies and Peak Postchallenge Viremia. Journal of Virology, 2009, 83, 4102-4111.	3.4	66
278	Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus. Journal of Virology, 1986, 59, 506-509.	3.4	65
279	Capped poly(A) leaders of variable lengths at the 5' ends of vaccinia virus late mRNAs. Journal of Virology, 1989, 63, 226-232.	3.4	65
280	Inverted terminal repetition in vaccinia virus DNA encodes early mRNAs. Nature, 1980, 285, 21-25.	27.8	64
281	Vaccinia Virus G9 Protein Is an Essential Component of the Poxvirus Entry-Fusion Complex. Journal of Virology, 2006, 80, 9822-9830.	3.4	64
282	Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection. Journal of Virology, 2009, 83, 7176-7184.	3.4	64
283	In vitro transcription of the inverted terminal repetition of the vaccinia virus genome: correspondence of initiation and cap sites. Journal of Virology, 1981, 37, 738-747.	3.4	64
284	Sequence homologies of diverse length tandem repetitions near ends of vaccinia virus genome suggest unequal crossing over. Nucleic Acids Research, 1982, 10, 5673-5679.	14.5	63
285	Correspondence of the Functional Epitopes of Poxvirus and Human Interleukin-18-Binding Proteins. Journal of Virology, 2001, 75, 9947-9954.	3.4	63
286	Repression of Vaccinia Virus Holliday Junction Resolvase Inhibits Processing of Viral DNA into Unit-Length Genomes. Journal of Virology, 2001, 75, 6460-6471.	3.4	63
287	Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17517-17521.	7.1	63
288	Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L ^{â^'} C7L ^{â^'} Mutant. MBio, 2015, 6, e01122.	4.1	63

#	Article	IF	Citations
289	The Vaccinia Virus A33R Protein Provides a Chaperone Function for Viral Membrane Localization and Tyrosine Phosphorylation of the A36R Protein. Journal of Virology, 2001, 75, 303-310.	3.4	62
290	The 1.51-A structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4240-4245.	7.1	62
291	Deciphering Poxvirus Gene Expression by RNA Sequencing and Ribosome Profiling. Journal of Virology, 2015, 89, 6874-6886.	3.4	62
292	Different Hâ€“2 subregions influence immunization against retrovirus and immunosuppression. Nature, 1987, 329, 729-732.	27.8	61
293	Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model. Journal of Virology, 2007, 81, 8989-8995.	3.4	61
294	Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity. Journal of Virology, 1987, 61, 1972-1977.	3.4	61
295	Vaccinia Virus A28L Gene Encodes an Essential Protein Component of the Virion Membrane with Intramolecular Disulfide Bonds Formed by the Viral Cytoplasmic Redox Pathway. Journal of Virology, 2004, 78, 2348-2356.	3.4	60
296	One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	60
297	Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Journal of Molecular Biology, 1988, 199, 399-413.	4.2	59
298	The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). Journal of Virology, 1990, 64, 4540-4548.	3.4	59
299	Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. Journal of Virology, 1994, 68, 4109-4116.	3.4	59
300	Identification of the vaccinia virus gene encoding nucleoside triphosphate phosphohydrolase I, a DNA-dependent ATPase. Journal of Virology, 1987, 61, 1738-1742.	3.4	58
301	Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition.. Journal of Experimental Medicine, 1990, 171, 875-887.	8.5	57
302	Vaccinia Virus Nonstructural Protein Encoded by the A11R Gene Is Required for Formation of the Virion Membrane. Journal of Virology, 2005, 79, 6598-6609.	3.4	57
303	Identification of factors specific for transcription of the late class of vaccinia virus genes. Journal of Virology, 1989, 63, 4224-4233.	3.4	57
304	Inhibition of host protein synthesis by vaccinia virus: fate of cell mRNA and synthesis of small poly (A)-rich polyribonucleotides in the presence of actinomycin D. Journal of Virology, 1975, 16, 34-42.	3.4	56
305	The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. Journal of Virology, 1997, 71, 3178-3187.	3.4	56
306	Early promoter-binding factor from vaccinia virions.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 6069-6073.	7.1	55

#	Article	IF	Citations
307	In vitro synthesis of vaccinia virus late mRNA containing a 5' poly(A) leader sequence.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8883-8887.	7.1	55
308	Golgi Network Targeting and Plasma Membrane Internalization Signals in Vaccinia Virus B5R Envelope Protein. Journal of Virology, 2000, 74, 3771-3780.	3.4	55
309	Multiprotein HIV Type 1 Clade B DNA/MVA Vaccine: Construction, Safety, and Immunogenicity in Macaques. AIDS Research and Human Retroviruses, 2004, 20, 654-665.	1.1	55
310	Lethal Monkeypox Virus Infection of CAST/EiJ Mice Is Associated with a Deficient Gamma Interferon Response. Journal of Virology, 2012, 86, 9105-9112.	3.4	55
311	Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. Journal of Virology, 1990, 64, 3537-3540.	3.4	55
312	Heterologously expressed serotonin 1A receptors couple to muscarinic K+ channels in heart.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5694-5698.	7.1	54
313	Retrograde Transport from Early Endosomes to the trans -Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions. Journal of Virology, 2016, 90, 8891-8905.	3.4	54
314	Phosphoprotein Component of Vaccinia Virions. Journal of Virology, 1973, 11, 961-970.	3.4	54
315	A transcription factor for expression of vaccinia virus late genes is encoded by an intermediate gene. Journal of Virology, 1991, 65, 3715-3720.	3.4	54
316	Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11511-11513.	7.1	53
317	Pervasive Initiation and 3â€²-End Formation of Poxvirus Postreplicative RNAs. Journal of Biological Chemistry, 2012, 287, 31050-31060.	3.4	53
318	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge. Journal of Virology, 2014, 88, 9579-9589.	3.4	53
319	Interaction and mutual stabilization of the two subunits of vaccinia virus mRNA capping enzyme coexpressed in Escherichia coli.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4023-4027.	7.1	52
320	Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14877-14882.	7.1	52
321	Poxvirus membrane biogenesis. Virology, 2015, 479-480, 619-626.	2.4	52
322	Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. Journal of Virology, 1992, 66, 1193-1198.	3.4	52
323	Role of Vaccinia Virus A20R Protein in DNA Replication: Construction and Characterization of Temperature-Sensitive Mutants. Journal of Virology, 2001, 75, 1656-1663.	3.4	51
324	Genetic evidence for vaccinia virus-encoded DNA polymerase: isolation of phosphonoacetate-resistant enzyme from the cytoplasm of cells infected with mutant virus. Journal of Virology, 1982, 43, 673-678.	3.4	51

#	Article	IF	Citations
325	Evidence against an Essential Role of COPII-Mediated Cargo Transport to the Endoplasmic Reticulum-Golgi Intermediate Compartment in the Formation of the Primary Membrane of Vaccinia Virus. Journal of Virology, 2003, 77, 11754-11766.	3.4	50
326	Vaccinia Virus G7L Protein Interacts with the A30L Protein and Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions. Journal of Virology, 2003, 77, 3418-3429.	3.4	50
327	Association of Vaccinia Virus Fusion Regulatory Proteins with the Multicomponent Entry/Fusion Complex. Journal of Virology, 2007, 81, 6286-6293.	3.4	50
328	Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5â^' CD4 T Cell Responses in Rhesus Macaques. Journal of Immunology, 2015, 195, 994-1005.	0.8	50
329	Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus. Journal of Virology, 1989, 63, 411-420.	3.4	50
330	Instability and reiteration of DNA sequences within the vaccinia virus genome.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 1614-1618.	7.1	49
331	HIV-1 Protease Cleaves Actin During Acute Infection of Human T-Lymphocytes. AIDS Research and Human Retroviruses, 1992, 8, 291-295.	1.1	49
332	Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants. Journal of Virology, 2016, 90, 7864-7879.	3.4	49
333	Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework. Journal of Virology, 1987, 61, 516-525.	3.4	49
334	Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10277-10281.	7.1	48
335	Vaccinia Virus F13L Protein with a Conserved Phospholipase Catalytic Motif Induces Colocalization of the B5R Envelope Glycoprotein in Post-Golgi Vesicles. Journal of Virology, 2001, 75, 7528-7542.	3.4	48
336	Characterization of a Newly Identified 35-Amino-Acid Component of the Vaccinia Virus Entry/Fusion Complex Conserved in All Chordopoxviruses. Journal of Virology, 2009, 83, 12822-12832.	3.4	48
337	Determination of the transcriptional regulatory region of a vaccinia virus late gene. Journal of Virology, 1987, 61, 75-80.	3.4	48
338	Nucleotide sequence required for resolution of the concatemer junction of vaccinia virus DNA. Journal of Virology, 1989, 63, 4354-4361.	3.4	48
339	Down Regulation of Gene Expression by the Vaccinia Virus D10 Protein. Journal of Virology, 1999, 73, 791-796.	3.4	48
340	Effects of Deletion or Stringent Repression of the H3L Envelope Gene on Vaccinia Virus Replication. Journal of Virology, 2000, 74, 7518-7528.	3.4	47
341	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. Journal of Virology, 2002, 76, 11484-11490.	3.4	47
342	Vaccinia Virus G4L Glutaredoxin Is an Essential Intermediate of a Cytoplasmic Disulfide Bond Pathway Required for Virion Assembly. Journal of Virology, 2002, 76, 467-472.	3.4	47

#	Article	IF	Citations
343	Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11291-11296.	7.1	47
344	Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. Virus Genes, 1987, 1, 7-21.	1.6	47
345	Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers. Journal of Virology, 1992, 66, 5610-5614.	3.4	47
346	Mapping and Functional Analysis of Interaction Sites within the Cytoplasmic Domains of the Vaccinia Virus A33R and A36R Envelope Proteins. Journal of Virology, 2003, 77, 4113-4126.	3.4	46
347	Modeling a Safer Smallpox Vaccination Regimen, for Human Immunodeficiency Virus Type 1â€“Infected Patients, in Immunocompromised Macaques. Journal of Infectious Diseases, 2003, 188, 1181-1191.	4.0	46
348	Vaccinia Virus A56/K2 Fusion Regulatory Protein Interacts with the A16 and G9 Subunits of the Entry Fusion Complex. Journal of Virology, 2008, 82, 5153-5160.	3.4	46
349	Predicted poxvirus FEN1-like nuclease required for homologous recombination, double-strand break repair and full-size genome formation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17921-17926.	7.1	46
350	Transcription of viral late genes is dependent on expression of the viral intermediate gene G8R in cells infected with an inducible conditional-lethal mutant vaccinia virus. Journal of Virology, 1992, 66, 6470-6479.	3.4	46
351	Assembly and Disassembly of the Capsid-Like External Scaffold of Immature Virions during Vaccinia Virus Morphogenesis. Journal of Virology, 2009, 83, 9140-9150.	3.4	45
352	Characterization of a 7-kilodalton subunit of vaccinia virus DNA-dependent RNA polymerase with structural similarities to the smallest subunit of eukaryotic RNA polymerase II. Journal of Virology, 1992, 66, 3003-3010.	3.4	45
353	The Vaccinia Virus A14.5L Gene Encodes a Hydrophobic 53-Amino-Acid Virion Membrane Protein That Enhances Virulence in Mice and Is Conserved among Vertebrate Poxviruses. Journal of Virology, 2000, 74, 4085-4092.	3.4	44
354	High-speed mass transit for poxviruses on microtubules. Nature Cell Biology, 2001, 3, E245-E246.	10.3	44
355	Multiprotein HIV Type 1 Clade B DNA and MVA Vaccines: Construction, Expression, and Immunogenicity in Rodents of the MVA Component. AIDS Research and Human Retroviruses, 2004, 20, 645-653.	1.1	44
356	Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage Î»â€“based recombination. Nature Methods, 2005, 2, 95-97.	19.0	44
357	Reflections on the early development of poxvirus vectors. Vaccine, 2013, 31, 4220-4222.	3.8	44
358	Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature, 1988, 335, 259-262.	27.8	43
359	Immune-defense molecules of Molluscum contagiosum virus, a human poxvirus. Trends in Microbiology, 2000, 8, 473-477.	7.7	43
360	Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19506-19511.	7.1	43

#	Article	IF	Citations
361	A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice. Molecular Therapy, 2007, 15, 1724-1733.	8.2	43
362	Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes. Journal of Virology, 1987, 61, 1286-1290.	3.4	43
363	Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial. PLoS ONE, 2015, 10, e0119629.	2.5	43
364	Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein. Journal of Virology, 2003, 77, 12266-12275.	3.4	42
365	Identification and expression of rpo19, a vaccinia virus gene encoding a 19-kilodalton DNA-dependent RNA polymerase subunit. Journal of Virology, 1992, 66, 971-982.	3.4	42
366	Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. PLoS ONE, 2015, 10, e0118486.	2.5	42
367	Histone mRNAs contain blocked and methylated 5â€² terminal sequences but lack methylated nucleosides at internal positions. Cell, 1977, 10, 113-120.	28.9	41
368	Construction and Characterization of a Triple-Recombinant Vaccinia Virus Encoding B7-1, Interleukin 12, and a Model Tumor Antigen. Journal of the National Cancer Institute, 1998, 90, 1881-1887.	6.3	41
369	Overexpression, purification, and late transcription factor activity of the 17-kilodalton protein encoded by the vaccinia virus A1L gene. Journal of Virology, 1993, 67, 5740-5748.	3.4	41
370	Identification of Second-Site Mutations That Enhance Release and Spread of Vaccinia Virus. Journal of Virology, 2002, 76, 11637-11644.	3.4	40
371	A Novel Mode of Poxvirus Superinfection Exclusion That Prevents Fusion of the Lipid Bilayers of Viral and Cellular Membranes. Journal of Virology, 2014, 88, 9751-9768.	3.4	40
372	Transition from rapid processive to slow nonprocessive polyadenylation by vaccinia virus poly(A) polymerase catalytic subunit is regulated by the net length of the poly(A) tail.. Genes and Development, 1992, 6, 1575-1586.	5.9	39
373	The Vaccinia Virus A9L Gene Encodes a Membrane Protein Required for an Early Step in Virion Morphogenesis. Journal of Virology, 2000, 74, 9701-9711.	3.4	39
374	Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras. Journal of Virology, 2004, 78, 2265-2276.	3.4	39
375	Vaccinia Virus A26 and A27 Proteins Form a Stable Complex Tethered to Mature Virions by Association with the A17 Transmembrane Protein. Journal of Virology, 2008, 82, 12384-12391.	3.4	39
376	A Glutaredoxin, Encoded by the G4L Gene of Vaccinia Virus, Is Essential for Virion Morphogenesis. Journal of Virology, 2000, 74, 9175-9183.	3.4	38
377	Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy. Journal of Virology, 2001, 75, 10300-10308.	3.4	38
378	Similarities in the Induction of Post-Golgi Vesicles by the Vaccinia Virus F13L Protein and Phospholipase D. Journal of Virology, 2002, 76, 7777-7789.	3.4	38

#	Article	IF	Citations
379	Direct Formation of Vaccinia Virus Membranes from the Endoplasmic Reticulum in the Absence of the Newly Characterized L2-Interacting Protein A30.5. Journal of Virology, 2013, 87, 12313-12326.	3.4	38
380	The D10 Decapping Enzyme of Vaccinia Virus Contributes to Decay of Cellular and Viral mRNAs and to Virulence in Mice. Journal of Virology, 2014, 88, 202-211.	3.4	38
381	Use of a bacterial expression vector to identify the gene encoding a major core protein of vaccinia virus. Journal of Virology, 1985, 56, 534-540.	3.4	38
382	De novo synthesis of the early transcription factor 70-kilodalton subunit is required for morphogenesis of vaccinia virions. Journal of Virology, 1996, 70, 7669-7677.	3.4	38
383	Envelope Formation Is Blocked by Mutation of a Sequence Related to the HKD Phospholipid Metabolism Motif in the Vaccinia Virus F13L Protein. Journal of Virology, 1999, 73, 1108-1117.	3.4	38
384	Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	38
385	Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Human Lymphocytes and Monocyte/Macrophages. Journal of Infectious Diseases, 1991, 163, 703-709.	4.0	37
386	Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2692-2697.	7.1	37
387	Vaccinia Virus A30L Protein Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions. Journal of Virology, 2001, 75, 5752-5761.	3.4	37
388	Determination of the Functional Epitopes of Human Interleukin-18-binding Protein by Site-directed Mutagenesis. Journal of Biological Chemistry, 2001, 276, 17380-17386.	3.4	37
389	Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion. Journal of Virology, 2009, 83, 1546-1554.	3.4	37
390	Why the smallpox virus stocks should not be destroyed. Science, 1993, 262, 1225-1226.	12.6	36
391	Molluscum Contagiosum Virus Interleukin-18 (IL-18) Binding Protein Is Secreted as a Full-Length Form That Binds Cell Surface Glycosaminoglycans through the C-Terminal Tail and a Furin-Cleaved Form with Only the IL-18 Binding Domain. Journal of Virology, 2003, 77, 2623-2630.	3.4	36
392	Two Distinct Low-pH Steps Promote Entry of Vaccinia Virus. Journal of Virology, 2007, 81, 8613-8620.	3.4	36
393	Transcriptional and translational mapping of a 6.6-kilobase-pair DNA fragment containing the junction of the terminal repetition and unique sequence at the left end of the vaccinia virus genome. Journal of Virology, 1981, 39, 722-732.	3.4	36
394	Participation of Vaccinia Virus L2 Protein in the Formation of Crescent Membranes and Immature Virions. Journal of Virology, 2011, 85, 2504-2511.	3.4	35
395	Intracellular Trafficking of a Palmitoylated Membrane-Associated Protein Component of Enveloped Vaccinia Virus. Journal of Virology, 2003, 77, 9008-9019.	3.4	34
396	Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine. Journal of Immunology, 2010, 185, 7262-7273.	0.8	34

#	Article	IF	Citations
397	Lipid Membranes in Poxvirus Replication. Viruses, 2010, 2, 972-986.	3.3	34
398	Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni). Virology, 2015, 475, 150-158.	2.4	34
399	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. Journal of Virology, 2016, 90, 8842-8854.	3.4	34
400	Evidence for an Essential Catalytic Role of the F10 Protein Kinase in Vaccinia Virus Morphogenesis. Journal of Virology, 2004, 78, 257-265.	3.4	33
401	Intravenous and Isolated Limb Perfusion Delivery of Wild Type and a Tumor-Selective Replicating Mutant Vaccinia Virus in Nonhuman Primates. Human Gene Therapy, 2006, 17, 31-45.	2.7	33
402	Abortive transcription products of vaccinia virus are guanylylated, methylated, and polyadenylylated. Journal of Virology, 1979, 31, 849-853.	3.4	33
403	Reversal of Anti-viral Effects of Rifampicin. Nature, 1970, 227, 1050-1051.	27.8	32
404	Transcription initiation factor activity of vaccinia virus capping enzyme is independent of mRNA guanylylation.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2860-2864.	7.1	32
405	Roles of Vaccinia Virus Ribonucleotide Reductase and Glutaredoxin in DNA Precursor Biosynthesis. Journal of Biological Chemistry, 1995, 270, 27415-27418.	3.4	32
406	Immunology 102 at poxvirus U: Avoiding apoptosis. Seminars in Immunology, 2001, 13, 67-72.	5.6	32
407	A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. Virology, 2008, 374, 506-514.	2.4	32
408	Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology, 2008, 380, 394-401.	2.4	32
409	Isolate- and Group-Specific Immune Responses to the Envelope Protein of Human Immunodeficiency Virus Induced by a Live Recombinant Vaccinia Virus in Macaques. AIDS Research and Human Retroviruses, 1989, 5, 23-32.	1.1	31
410	Gp120-Alum Boosting of a Gag-Pol-Env DNA/MVA AIDS Vaccine: Poorer Control of a Pathogenic Viral Challenge. AIDS Research and Human Retroviruses, 2003, 19, 891-900.	1.1	31
411	Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology, 2007, 359, 227-232.	2.4	31
412	Vaccinia Virus E2L Null Mutants Exhibit a Major Reduction in Extracellular Virion Formation and Virus Spread. Journal of Virology, 2008, 82, 4215-4226.	3.4	31
413	A role for the host coatomer and KDEL receptor in early vaccinia biogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 163-168.	7.1	31
414	CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection. Journal of Virology, 2015, 89, 4690-4695.	3.4	31

#	Article	IF	Citations
415	Recombinant Vaccinia Viruses as New Live Vaccines. Biotechnology and Genetic Engineering Reviews, 1984, 2, 383-407.	6.2	30
416	Purification and use of vaccinia virus messenger RNA capping enzyme. Methods in Enzymology, 1990, 181, 170-180.	1.0	30
417	Interaction of the Vaccinia Virus RNA Polymerase-Associated 94-Kilodalton Protein with the Early Transcription Factor. Journal of Virology, 2009, 83, 12018-12026.	3.4	30
418	A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	30
419	Natural killer cells expanded in vivoÂor ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses. PLoS Pathogens, 2020, 16, e1008505.	4.7	30
420	Regulation of Synthesis of Two Immunologically Distinct Nucleic Acid-Dependent Nucleoside Triphosphate Phosphohydrolases in Vaccinia Virus-Infected HeLa Cells. Journal of Virology, 1974, 14, 578-586.	3.4	30
421	Recombinant CD4-Pseudomonas Exotoxin Hybrid Protein Displays HIV-Specific Cytotoxicity without Affecting MHC Class II-Dependent Functions. AIDS Research and Human Retroviruses, 1990, 6, 795-804.	1.1	29
422	Vaccinia Virus G1 Protein, a Predicted Metalloprotease, Is Essential for Morphogenesis of Infectious Virions but Not for Cleavage of Major Core Proteins. Journal of Virology, 2004, 78, 6855-6863.	3.4	29
423	Immunogenicity in Macaques of the Clinical Product for a Clade B DNA/MVA HIV Vaccine: Elicitation of IFN-Î³, IL-2, and TNF-Î± Coproducing CD4 and CD8 T Cells. AIDS Research and Human Retroviruses, 2007, 23, 1555-1562.	1.1	29
424	Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge. Journal of Virology, 2008, 82, 8022-8029.	3.4	29
425	A Conserved Sequence within the H2 Subunit of the Vaccinia Virus Entry/Fusion Complex Is Important for Interaction with the A28 Subunit and Infectivity. Journal of Virology, 2008, 82, 6244-6250.	3.4	29
426	Cellular DNA Ligase I Is Recruited to Cytoplasmic Vaccinia Virus Factories and Masks the Role of the Vaccinia Ligase in Viral DNA Replication. Cell Host and Microbe, 2009, 6, 563-569.	11.0	29
427	Topology of Endoplasmic Reticulumâ€Associated Cellular and Viral Proteins Determined with Splitâ€<scp>GFP</scp>. Traffic, 2015, 16, 787-795.	2.7	29
428	Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles. Journal of Virology, 2018, 92, .	3.4	29
429	Signature for Long-Term Vaccine-Mediated Control of a Simian and Human Immunodeficiency Virus 89.6P Challenge: Stable Low-Breadth and Low-Frequency T-Cell Response Capable of Coproducing Gamma Interferon and Interleukin-2. Journal of Virology, 2005, 79, 3243-3253.	3.4	28
430	Congregation of Orthopoxvirus Virions in Cytoplasmic A-Type Inclusions Is Mediated by Interactions of a Bridging Protein (A26p) with a Matrix Protein (ATIp) and a Virion Membrane-Associated Protein (A27p). Journal of Virology, 2010, 84, 7592-7602.	3.4	28
431	Enigmatic origin of the poxvirus membrane from the endoplasmic reticulum shown by 3D imaging of vaccinia virus assembly mutants. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11001-E11009.	7.1	28
432	Protein Kinase Activity from Vaccinia Virions: Solubilization and Separation into Heat-Labile and Heat-Stable Components. Journal of Virology, 1973, 12, 684-689.	3.4	28

#	Article	IF	Citations
433	Synthesis of mRNA guanylyltransferase and mRNA methyltransferases in cells infected with vaccinia virus. Journal of Virology, 1977, 21, 475-483.	3.4	28
434	Poxvirus vectors: cytoplasmic expression of transferred genes. Current Opinion in Genetics and Development, 1993, 3, 86-90.	3.3	27
435	Topology of epitope-tagged F13L protein, a major membrane component of extracellular vaccinia virions. Virology, 2003, 308, 233-242.	2.4	27
436	Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3720-3725.	7.1	27
437	Modification of the cascade model for regulation of vaccinia virus gene expression: purification of a prereplicative, late-stage-specific transcription factor. Journal of Virology, 1994, 68, 3443-3447.	3.4	27
438	Repression of the A8L Gene, Encoding the Early Transcription Factor 82-Kilodalton Subunit, Inhibits Morphogenesis of Vaccinia Virions. Journal of Virology, 1998, 72, 104-112.	3.4	27
439	Interaction of the 82-kDa subunit of the vaccinia virus early transcription factor heterodimer with the promoter core sequence directs downstream DNA binding of the 70-kDa subunit.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7540-7545.	7.1	26
440	Regulation of Viral Intermediate Gene Expression by the Vaccinia Virus B1 Protein Kinase. Journal of Virology, 2001, 75, 4048-4055.	3.4	26
441	Vaccinia Virus H7 Protein Contributes to the Formation of Crescent Membrane Precursors of Immature Virions. Journal of Virology, 2009, 83, 8439-8450.	3.4	26
442	Duplication of the A17L Locus of Vaccinia Virus Provides an Alternate Route to Rifampin Resistance. Journal of Virology, 2014, 88, 11576-11585.	3.4	26
443	Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging. Virology, 2014, 449, 120-132.	2.4	26
444	Vaccinia Virus C9 Ankyrin Repeat/F-Box Protein Is a Newly Identified Antagonist of the Type I Interferon-Induced Antiviral State. Journal of Virology, 2018, 92, .	3.4	26
445	Ordered assembly of a functional preinitiation transcription complex, containing vaccinia virus early transcription factor and RNA polymerase, on an immobilized template. Journal of Virology, 1994, 68, 6052-6056.	3.4	26
446	Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Molecular and Biochemical Parasitology, 1991, 48, 89-99.	1.1	25
447	Cell-specific posttranslational events affect functional expression at the plasma membrane but not tetrodotoxin sensitivity of the rat brain IIA sodium channel alpha-subunit expressed in mammalian cells. Journal of Neuroscience, 1992, 12, 268-277.	3.6	25
448	Vaccinia Virus Mutants with Alanine Substitutions in the Conserved G5R Gene Fail To Initiate Morphogenesis at the Nonpermissive Temperature. Journal of Virology, 2004, 78, 10238-10248.	3.4	25
449	Physical and Functional Interactions between Vaccinia Virus F10 Protein Kinase and Virion Assembly Proteins A30 and G7. Journal of Virology, 2004, 78, 266-274.	3.4	25
450	Drosophila S2 Cells Are Non-Permissive for Vaccinia Virus DNA Replication Following Entry via Low pH-Dependent Endocytosis and Early Transcription. PLoS ONE, 2011, 6, e17248.	2.5	25

#	Article	IF	Citations
451	Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells. PLoS Pathogens, 2020, 16, e1008845.	4.7	25
452	Deoxyribonucleic Acid-Dependent Nucleotide Phosphohydrolase Activity in Purified Vaccinia Virus. Journal of Virology, 1972, 10, 866-868.	3.4	25
453	pUV I: a new vaccinia virus insertion and expression vector. Nucleic Acids Research, 1987, 15, 7192-7192.	14.5	24
454	Viruses know more than one way to don a cap. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3283-3284.	7.1	24
455	Reverse Genetics Analysis of Poxvirus Intermediate Transcription Factors. Journal of Virology, 2012, 86, 9514-9519.	3.4	24
456	Analysis of Viral Membranes Formed in Cells Infected by a Vaccinia Virus L2-Deletion Mutant Suggests Their Origin from the Endoplasmic Reticulum. Journal of Virology, 2013, 87, 1861-1871.	3.4	24
457	Mapping vaccinia virus DNA replication origins at nucleotide level by deep sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10908-10913.	7.1	23
458	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology, 2017, 91, .	3.4	23
459	SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells. PLoS Pathogens, 2019, 15, e1007710.	4.7	23
460	Similar Effect of Rifampin and Other Rifamycin Derivatives on Vaccinia Virus Morphogenesis. Journal of Virology, 1971, 8, 225-231.	3.4	23
461	Virus entryâ€”an unwilling collaboration by the cell. Current Opinion in Virology, 2013, 3, 1-2.	5.4	22
462	A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Research, 2013, 41, 6609-6617.	14.5	22
463	Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. AIDS Research and Human Retroviruses, 2017, 33, 880-888.	1.1	22
464	Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses. Virology, 2017, 511, 19-22.	2.4	22
465	Human Host Range Restriction of the Vaccinia Virus C7/K1 Double Deletion Mutant Is Mediated by an Atypical Mode of Translation Inhibition. Journal of Virology, 2018, 92, .	3.4	22
466	Translation of specific vaccinia virus RNAs purified as RNA-DNA hybrids on potassium iodide gradients. Nucleic Acids Research, 1979, 6, 3599-3612.	14.5	21
467	Expression of ion channels and receptors in Xenopus oocytes using vaccinia virus. FASEB Journal, 1991, 5, 2209-2216.	0.5	21
468	Disulfide Bonds and Membrane Topology of the Vaccinia Virus A17L Envelope Protein. Journal of Virology, 2000, 74, 2438-2442.	3.4	21

#	Article	IF	Citations
469	Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2002, 76, 6376-6381.	3.4	21
470	Role of Receptor-Mediated Endocytosis in the Formation of Vaccinia Virus Extracellular Enveloped Particles. Journal of Virology, 2005, 79, 4080-4089.	3.4	21
471	Sequence-Independent Targeting of Transmembrane Proteins Synthesized within Vaccinia Virus Factories to Nascent Viral Membranes. Journal of Virology, 2007, 81, 2646-2655.	3.4	21
472	Vaccinia Virus Polyriboadenylate Polymerase: Covalent Linkage of the Product with Polyribonucleotide and Polydeoxyribonucleotide Primers. Journal of Virology, 1974, 14, 86-98.	3.4	21
473	Transcriptional mapping of the vaccinia virus DNA polymerase gene. Journal of Virology, 1985, 53, 312-315.	3.4	21
474	Vaccinia Virus L2 Protein Associates with the Endoplasmic Reticulum near the Growing Edge of Crescent Precursors of Immature Virions and Stabilizes a Subset of Viral Membrane Proteins. Journal of Virology, 2011, 85, 12431-12441.	3.4	20
475	Identification of Vaccinia Virus Replisome and Transcriptome Proteins by Isolation of Proteins on Nascent DNA Coupled with Mass Spectrometry. Journal of Virology, 2017, 91, .	3.4	20
476	Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3759-3767.	7.1	20
477	Mutational analysis of a predicted zinc-binding motif in the 26-kilodalton protein encoded by the vaccinia virus A2L gene: correlation of zinc binding with late transcriptional transactivation activity. Journal of Virology, 1993, 67, 5749-5753.	3.4	20
478	Immunogenicity of Recombinant Vaccinia Viruses that Display the HIV Type 1 Envelope Glycoprotein on the Surface of Infectious Virions. AIDS Research and Human Retroviruses, 1997, 13, 1497-1500.	1.1	19
479	Interaction between the G3 and L5 proteins of the vaccinia virus entryâ€“fusion complex. Virology, 2011, 412, 278-283.	2.4	19
480	The 2.1 Ã… structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex. Scientific Reports, 2018, 8, 16807.	3.3	19
481	Common Sequence at the 5â€² Ends of the Segmented RNA Genomes of Influenza A and B Viruses. Journal of Virology, 1978, 25, 312-318.	3.4	19
482	High level protein expression in mammalian cells using a safe viral vector: Modified vaccinia virus Ankara. Protein Expression and Purification, 2007, 56, 269-278.	1.3	18
483	Elimination of A-type inclusion formation enhances cowpox virus replication in mice: Implications for orthopoxvirus evolution. Virology, 2014, 452-453, 59-66.	2.4	18
484	Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection. Journal of Virology, 2017, 91, .	3.4	18
485	Transcription of a vaccinia virus late promoter template: requirement for the product of the A2L intermediate-stage gene. Journal of Virology, 1996, 70, 4444-4450.	3.4	18
486	Clearance of Recombinant Vaccinia Virus Expressing IL-2: Role of Local Host Immune Responses. Cellular Immunology, 1993, 152, 499-509.	3.0	17

#	Article	IF	Citations
487	Association of the Vaccinia Virus A11 Protein with the Endoplasmic Reticulum and Crescent Precursors of Immature Virions. Journal of Virology, 2013, 87, 10195-10206.	3.4	17
488	Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus. Journal of Virology, 2020, 94, .	3.4	17
489	Vaccinia and other poxvirus expression vectors. Current Opinion in Biotechnology, 1992, 3, 518-522.	6.6	16
490	Quaternary Structure and Cleavage Specificity of a Poxvirus Holliday Junction Resolvase. Journal of Biological Chemistry, 2006, 281, 11618-11626.	3.4	16
491	High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5Î±-Restrictive Macaques. Journal of Immunology, 2016, 197, 3586-3596.	0.8	16
492	Vaccinia Virus Ankyrin-Repeat/F-Box Protein Targets Interferon-Induced IFITs for Proteasomal Degradation. Cell Reports, 2019, 29, 816-828.e6.	6.4	16
493	The Conserved Poxvirus L3 Virion Protein Is Required for Transcription of Vaccinia Virus Early Genes. Journal of Virology, 2005, 79, 14719-14729.	3.4	15
494	Formation of Orthopoxvirus Cytoplasmic A-Type Inclusion Bodies and Embedding of Virions Are Dynamic Processes Requiring Microtubules. Journal of Virology, 2012, 86, 5905-5914.	3.4	15
495	Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins. MBio, 2017, 8, .	4.1	15
496	Unique Temperature-Sensitive Defect in Vaccinia Virus Morphogenesis Maps to a Single Nucleotide Substitution in the A30L Gene. Journal of Virology, 2001, 75, 11222-11226.	3.4	14
497	Vaccinia Virus Encodes I5, a Small Hydrophobic Virion Membrane Protein That Enhances Replication and Virulence in Mice. Journal of Virology, 2008, 82, 10071-10078.	3.4	14
498	Products and substrate/template usage of vaccinia virus DNA primase. Virology, 2009, 383, 136-141.	2.4	14
499	Genome Sequence of Erythromelalgia-Related Poxvirus Identifies it as an Ectromelia Virus Strain. PLoS ONE, 2012, 7, e34604.	2.5	14
500	Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology, 2007, 366, 424-432.	2.4	13
501	Sequence-Divergent Chordopoxvirus Homologs of the O3 Protein Maintain Functional Interactions with Components of the Vaccinia Virus Entry-Fusion Complex. Journal of Virology, 2012, 86, 1696-1705.	3.4	13
502	Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus. Virology, 2015, 481, 161-165.	2.4	13
503	Poxviruses Encode a Reticulon-Like Protein that Promotes Membrane Curvature. Cell Reports, 2016, 14, 2084-2091.	6.4	13
504	Fine structure marker rescue of temperature-sensitive mutations of vaccinia virus within a central conserved region of the genome. Journal of Virology, 1985, 56, 1027-1029.	3.4	13

#	Article	IF	Citations
505	A New Vaccinia Virus Intermediate Transcription Factor. Journal of Virology, 1998, 72, 6880-6883.	3.4	13
506	Transcriptional Repression and RNA Silencing Act Synergistically To Demonstrate the Function of the Eleventh Component of the Vaccinia Virus Entry-Fusion Complex. Journal of Virology, 2012, 86, 293-301.	3.4	12
507	Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells. Journal of Virology, 2021, 95, e0085221.	3.4	12
508	Production of pro-opiomelanocortin (POMC) by a vaccinia virus transient expression system and in vitro processing of the expressed prohormone by POMC-converting enzyme. FEBS Letters, 1989, 248, 43-47.	2.8	11
509	Recombinant Protein Synthesis in Chinese Hamster Ovary Cells Using a Vaccinia Virus/Bacteriophage T7 Hybrid Expression System. Journal of Biological Chemistry, 1996, 271, 16962-16966.	3.4	11
510	Colinearity of RNAs with the vaccinia virus genome: anomalies with two complementary early and late RNAs result from a small deletion or rearrangement within the inverted terminal repetition. Journal of Virology, 1982, 42, 447-455.	3.4	11
511	Effects of a Temperature Sensitivity Mutation in the J1R Protein Component of a Complex Required for Vaccinia Virus Assembly. Journal of Virology, 2005, 79, 8046-8056.	3.4	10
512	Interactions of the Vaccinia Virus A19 Protein. Journal of Virology, 2013, 87, 10710-10720.	3.4	10
513	Molluscum Contagiosum Virus Transcriptome in Abortively Infected Cultured Cells and a Human Skin Lesion. Journal of Virology, 2016, 90, 4469-4480.	3.4	10
514	Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses. Journal of Virology, 2019, 93, .	3.4	10
515	Dinucleotide Sequences at the 5â€² Ends of Vaccinia Virus mRNA's Synthesized In Vitro. Journal of Virology, 1980, 36, 601-605.	3.4	10
516	Synthesis of Vaccinia Viral Proteins in Cytoplasmic Extracts. Journal of Virology, 1969, 4, 416-422.	3.4	10
517	Immunization with Multiple Vaccine Modalities Induce Strong HIV-Specific Cellular and Humoral Immune Responses. Viral Immunology, 2012, 25, 423-432.	1.3	9
518	Vaccinia Virus A19 Protein Participates in the Transformation of Spherical Immature Particles to Barrel-Shaped Infectious Virions. Journal of Virology, 2013, 87, 10700-10709.	3.4	9
519	A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. Virology, 2017, 501, 107-114.	2.4	9
520	Origin of the poxviral membrane: A 50-year-old riddle. PLoS Pathogens, 2018, 14, e1007002.	4.7	9
521	Molecular cloning of the terminal hairpin of vaccinia virus DNA as an imperfect palindrome in an Escherichia coli plasmid. Gene, 1985, 37, 221-228.	2.2	8
522	Expression of the highly conserved vaccinia virus E6 protein is required for virion morphogenesis. Virology, 2009, 386, 478-485.	2.4	8

#	Article	IF	Citations
523	RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog. Journal of Virology, 2018, 92, .	3.4	8
524	Rifamycins: Modulation of Specific Anti-Poxviral Activity by Small Substitutions on the Piperazinyliminomethyl Side Chain. Antimicrobial Agents and Chemotherapy, 1972, 2, 181-185.	3.2	7
525	Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome. Journal of Virology, 2020, 94, .	3.4	7
526	Uses of vaccinia virus as a vector for the production of live recombinant vaccines. BioEssays, 1984, 1, 120-124.	2.5	6
527	Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxviruses. Virology, 2015, 483, 209-217.	2.4	6
528	Specific Anchoring and Local Translation of Poxviral ATI mRNA at Cytoplasmic Inclusion Bodies. Journal of Virology, 2020, 94, .	3.4	6
529	Synthesis of Vaccinia Viral Proteins in Cytoplasmic Extracts. Journal of Virology, 1969, 4, 596-602.	3.4	6
530	Decoding poxvirus genome. Oncotarget, 2015, 6, 28513-28514.	1.8	6
531	Anti-HIV Effects of CD4-Pseudomonas Exotoxin on Human Lymphocyte and Monocyte/Macrophage Cell Lines. Annals of the New York Academy of Sciences, 1990, 616, 149-154.	3.8	5
532	[2] Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4. Methods in Enzymology, 1993, 221, 12-18.	1.0	5
533	[12] Expression, purification, and characterization of vaccinia virus-encoded RNA and poly(A) polymerases. Methods in Enzymology, 1996, 275, 208-227.	1.0	5
534	Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation. Virology, 2010, 396, 160-168.	2.4	5
535	Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus. Virology, 2010, 398, 187-193.	2.4	5
536	Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines, 2017, 5, 52.	4.4	5
537	Investigating Viruses during the Transformation of Molecular Biology. Journal of Biological Chemistry, 2017, 292, 3958-3969.	3.4	4
538	HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. Heliyon, 2017, 3, e00339.	3.2	4
539	Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells. Journal of Virology, 2021, 95, e0110421.	3.4	4
540	Expression systems: Editorial overview. Current Opinion in Biotechnology, 1990, 1, 3-4.	6.6	3

#	Article	IF	Citations
541	Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis, Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins. Journal of Virology, 2017, 91, .	3.4	3
542	Loss of the Vaccinia Virus 35-Amino-Acid Hydrophobic O3 Protein Is Partially Compensated by Mutations in the Transmembrane Domains of Other Entry Proteins. Journal of Virology, 2021, 95, .	3.4	3
543	Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex. Journal of Virology, 2020, 94, .	3.4	2
544	Research with variola virus after smallpox eradication: Development of a mouse model for variola virus infection. PLoS Pathogens, 2021, 17, e1009911.	4.7	2
545	Interferon Î±/Î² Decoy Receptor Encoded by a Variant in the Dryvax Smallpox Vaccine Contributes to Virulence and Correlates with Severe Vaccine Side Effects. MBio, 2022, 13, e0010222.	4.1	2
546	Investigating Viruses During the Transformation of Molecular Biology: Part II. Annual Review of Virology, 2020, 7, 15-36.	6.7	0